This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron

This study has been completed.
Information provided by:
University Hospital Inselspital, Berne Identifier:
First received: April 28, 2009
Last updated: March 23, 2011
Last verified: March 2011
Chronic pain is associated with hypersensitivity of the central nervous system. The drug under investigation (tropisetron) has been shown in animal studies to attenuate central hypersensitivity. It has therefore the potential to be effective in chronic pain. We compare two doses of tropisetron with placebo in patients with chronic pain. We measure pain intensity and parameters that assess central hypersensitivity.

Condition Intervention Phase
Pain Chronic Disease Drug: Tropisetron 2 mg Drug: Tropisetron 5mg Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron

Resource links provided by NLM:

Further study details as provided by University Hospital Inselspital, Berne:

Primary Outcome Measures:
  • Pain intensity (VAS score) [ Time Frame: 2 h ]

Secondary Outcome Measures:
  • Measures of central hypersensitivity [ Time Frame: 2 h ]

Enrollment: 30
Study Start Date: March 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Crossover study
Crossover study
Drug: Tropisetron 2 mg
Antagonist of the 5HT3 receptor.
Placebo Comparator: 2
Crossover Study
Drug: Tropisetron 5mg
Antagonist of the 5HT3 receptor.
Placebo Comparator: 3
Crossover Study
Drug: Placebo
NHCL 0,9%

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic musculoskeletal pain
  • Pain duration at least 6 months

Exclusion Criteria:

  • Pregnancy
  • Breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00889499

Dep. of Anesthesiology and Pain Therapy, Bern University Hospital, Inselspital
Bern, Switzerland, 3010
Sponsors and Collaborators
University Hospital Inselspital, Berne
Study Director: Michele Curatolo, Prof Inselspital, Bern University Hospital
  More Information

Responsible Party: Michele Curatolo / Prof., Inselspital, Bern University Hospital, Switzerland Identifier: NCT00889499     History of Changes
Other Study ID Numbers: KEK 146/04
Study First Received: April 28, 2009
Last Updated: March 23, 2011

Additional relevant MeSH terms:
Chronic Disease
Musculoskeletal Pain
Immune System Diseases
Disease Attributes
Pathologic Processes
Muscular Diseases
Musculoskeletal Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017